Search

Search Constraints

You searched for: Author/Creator Sun, J.

Search Results

7. 2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib. (September 2015)

9. 435 Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. (September 2015)

10. 86P Efficacy and safety of IBI110 (anti-LAG-3 mAb) in combination with sintilimab (anti-PD-1 mAb) in advanced squamous non-small cell lung cancer (sqNSCLC): Updated results of the phase Ib study. (December 2022)